Showing results (101-110 of 236) with videos related to

Sort By:
Pageof 24
HIV Medicine|June 30, 2016
HIV drug resistance levels in adults failing first-line antiretroviral therapy in an urban and a rural setting in South AfricaT M Rossouw, M Nieuwoudt, J Manasa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 6, 2022
Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infectionTongai G Maponga, Montenique Jeffries, Houriiyah Tegally, et al.
British Journal of Cancer|December 19, 2001
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinomaN A Wong, L Brett, M Stewart, et al.
Nature Communications|October 30, 2021
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South AfricaKrishna P Reddy, Kieran P Fitzmaurice, Justine A Scott, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2021
Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South AfricaKrishna P Reddy, Kieran P Fitzmaurice, Justine A Scott, et al.
Open Forum Infectious Diseases|December 4, 2023
Clinical Outcomes After Viremia Among People Receiving Dolutegravir vs Efavirenz-Based First-line Antiretroviral Therapy in South AfricaKwabena Asare, Lara Lewis, Johan van der Molen, et al.
Medrxiv : the Preprint Server for Health Sciences|July 2, 2024
HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre longitudinal study (DTG RESIST)Matthias Egger, Mamatha Sauermann, Tom Loosli, et al.
BMJ Open|August 22, 2024
HIV-1 subtype-specific drug resistance on dolutegravir-based antiretroviral therapy: protocol for a multicentre study (DTG RESIST)Matthias Egger, Mamatha Sauermann, Tom Loosli, et al.
Medrxiv : the Preprint Server for Health Sciences|July 18, 2023
Clinical outcomes after the introduction of dolutegravir for second-line antiretroviral therapy in South Africa: a retrospective cohort studyKwabena Asare, Yukteshwar Sookrajh, Johan van der Molen, et al.
The Lancet. Global Health|December 24, 2023
Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort studyKwabena Asare, Yukteshwar Sookrajh, Johan van der Molen, et al.
Pageof 24